← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
251	251 Molecular Partners MOLN $140M	5	+1	+25%	$13.8M
252	252 Shuttle Pharmaceuticals SHPH $26.3M	5	-3	-38%	$338K
253	SRNE 253 DELISTED Sorrento Therapeutics, Inc. SRNE	5	+1	+25%	$70
254	254 Apollomics APLM $61.5M	4	0	0%	$224K
255	APTO 255 DELISTED Aptose Biosciences, Inc. APTO	4	0	0%	$38.7K
256	256 Propanc Biopharma PPCB $3.32M	4	-2	-33%	$71.5K
257	ACHL 257 DELISTED Achilles Therapeutics ACHL	3	0	0%	$98.9K
258	258 CytoMed Therapeutics GDTC $10.1M	3	0	0%	$12.2K
259	259 DELISTED Arcellx ACLX	2	-238	-99%	$3.43M
260	260 DELISTED Eagle Pharmaceuticals, Inc. EGRX	2	0	0%	$8.28K
261	ARAV 261 DELISTED Aravive, Inc. Common Stock ARAV	1	0	0%	$373
262	262 DELISTED Assertio ASRT	1	-64	-98%	$118
263	263 DELISTED Blueprint Medicines BPMC	1	-1	-50%	$129
264	264 DELISTED Carisma Therapeutics CARM	1	-2	-67%	$4
265	265 DELISTED CASI Pharmaceuticals CASI	1	0	0%	$17
266	266 DELISTED Day One Biopharmaceuticals DAWN	1	-207	-100%	$3.55K
267	267 DELISTED eFFECTOR Therapeutics, Inc. Common Stock EFTR	1	0	0%	–
268	268 DELISTED Exact Sciences EXAS	1	-6	-86%	$1.81K
269	269 DELISTED Immunogen Inc IMGN	1	0	0%	$269
270	270 DELISTED Merrimack Pharmaceuticals, Inc. MACK	1	0	0%	–
271	MYOV 271 DELISTED Myovant Sciences Ltd. MYOV	1	0	0%	$27
272	272 DELISTED NKGen Biotech, Inc. Common Stock NKGN	1	0	0%	$165K
273	NYMX 273 DELISTED Nymox Pharmaceutical Corp NYMX	1	0	0%	$4.21K
274	274 DELISTED Ocean Biomedical, Inc. Common Stock OCEA	1	0	0%	–
275	275 DELISTED Omega Therapeutics, Inc. Common Stock OMGA	1	0	0%	–